

*Cont'd*  
*AJ*

29. The composition of claim 25, wherein the cytokines isolated comprises IFN-beta and IL-10.

REMARKS

Applicants thank the Examiner for his time and thoughts during the interview conducted on January 15, 2002.

From the above referenced Office action and the interview with the Examiner on January 15, it is understood that the claims of the instant application are drawn to three distinct inventions. Claims 1-10 are drawn to a composition containing a mixture of human cytokines. Claims 11-21 are drawn to a method of producing a mixture of cytokines for use as a therapeutic composition. Claims 22-24 are drawn to methods of treating diseases by administrating the cytokines composition of claims 1-10.

*A*

In response, the applicants elect the composition claims 1-10 for continued prosecution without traverse. Non-elected claims 11-24 have been canceled. Applicants also cancelled claims 3-8 and added new claims 25-29. By cancellation of claims 3-8, Applicants obviated the objection raised by Examiner in Groups I - CCLIII. Claims 25 - 29 are added to better define the scope of the invention. Claims 1-2, 25-29 are pending.

If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 838-4404.

Respectfully submitted,



C. Amy Ng Smith  
Registration No. 42,931

Date: January 16, 2002

Correspondence Address:

Customer No. 22918  
Perkins Coie, LLP  
101 Jefferson Drive,  
Menlo Park, CA 94025-1114  
Phone: (650) 838-4300